Valuation: Jasper Therapeutics, Inc.

Market Cap 9.55M 8.37M 7.72M 7.22M 13.55M 901M 13.83M 92.74M 35.88M 445M 35.85M 35.07M 1.54B P/E 2026 *
-0.36x
P/E 2027 * -0.26x
Enterprise Value -273M -239M -220M -206M -387M -25.74B -395M -2.65B -1.03B -12.72B -1.02B -1B -44.1B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jasper Therapeutics, Inc.

1 day-22.99%
1 week-24.72%
Current month-58.87%
1 month-61.70%
3 months-67.52%
6 months-80.62%
Current year-81.37%
1 week 0.34
Extreme 0.34
0.52
1 month 0.34
Extreme 0.34
0.86
Current year 0.34
Extreme 0.34
2.07
1 year 0.34
Extreme 0.34
7.19
3 years 0.34
Extreme 0.34
31.01
5 years 0.34
Extreme 0.34
188.8
10 years 0.34
Extreme 0.34
188.8
Manager TitleAgeSince
Chief Executive Officer 54 2026-01-05
Director of Finance/CFO 54 2023-09-21
Chief Tech/Sci/R&D Officer 68 2023-03-22
Director TitleAgeSince
Director/Board Member 54 2026-01-05
Director/Board Member 70 2021-09-03
Director/Board Member 58 2021-09-23
Date Insider Type Main position Quantity % Market Cap.
02-05Free

Chief Executive Officer

500,000 1.7867%
01-01Free

Chief Financial Officer

90,000 0.3216%
01-01Free

Chief Executive Officer

90,000 0.3216%
Change 5-day change 1-year change 3-year change Capi.($)
-22.99%-24.72%-93.79%-97.47% 9.55M
+0.33%+1.37%+63.66%+123.67% 55.63B
+0.82%+15.05%+79.52%+88.67% 52.25B
+1.36%+0.36%-14.52%-14.67% 23.07B
-1.04%+7.91%+3.91%+413.05% 22.41B
+6.90%+14.90%+37.70%-1.75% 17.32B
-1.10%+4.00%+29.97%-32.75% 15.94B
+2.89%+5.51%+25.42%+188.41% 13.77B
-3.35%+8.96%+134.32%+282.61% 13.47B
+6.32%+13.25%+35.82% - 12.43B
Average -0.99%+1.83%+30.20%+105.53% 22.63B
Weighted average by Cap. +1.08%+5.13%+49.42%+122.86%

Financials

2026 *2027 *
Net sales - -
Net income -36.99M -32.43M -29.9M -27.99M -52.48M -3.49B -53.57M -359M -139M -1.72B -139M -136M -5.98B -64.38M -56.45M -52.03M -48.71M -91.34M -6.07B -93.24M -625M -242M -3B -242M -236M -10.41B
Net Debt -282M -248M -228M -214M -401M -26.64B -409M -2.74B -1.06B -13.16B -1.06B -1.04B -45.65B -555M -486M -448M -420M -787M -52.32B -803M -5.39B -2.08B -25.86B -2.08B -2.04B -89.66B
Logo Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Employees
22
Date Price Change Volume
26-06-26 US$0.3410 -22.99% 1,353,034
26-06-25 US$0.4428 -9.74% 319,885
26-06-24 US$0.4906 +0.33% 279,370
26-06-23 US$0.4890 -2.49% 650,197
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.3410USD
Average target price
8.625USD
Spread / Average Target
+2,429.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JSPR Stock